Additionally, a new selective FGFR-targeting multi-kinase inhibitor, tinengotinib, demonstrated a 94.7% DCR in FGFR2 fusion/rearrangement CCA, including FGFR-resistant patients, during a phase 2 trial.63 The gene discussed is FGFR2; the disease is cholangiocarcinoma.